相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effect of Grapefruit Juice on the Pharmacokinetics of Nilotinib in Healthy Participants
Ophelia Q. P. Yin et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients
Brett E. Houk et al.
CLINICAL CANCER RESEARCH (2009)
Sunitinib (Sutent, SU11248), a Small-Molecule Receptor Tyrosine Kinase Inhibitor, Blocks Function of the ATP-Binding Cassette (ABC) Transporters P-Glycoprotein (ABCB1) and ABCG2
Suneet Shukla et al.
DRUG METABOLISM AND DISPOSITION (2009)
No clinically relevant CYP3A induction after St. John's wort with low hyperforin content in healthy volunteers
Silke C. Mueller et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Influence of Solute Carriers on the Pharmacokinetics of CYP3A4 Probes
R. M. Franke et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Quantification of sunitinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry
Patton Minkin et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2008)
Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib
Nielka R. van Erp et al.
CLINICAL CANCER RESEARCH (2007)
Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors
Val R. Adams et al.
CLINICAL THERAPEUTICS (2007)
Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice
D. G. Bailey et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Intestinal drug transporter expression and the impact of grapefruit juice in humans
H. Glaeser et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Approval summary: Sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma
Vicki L. Goodman et al.
CLINICAL CANCER RESEARCH (2007)
Pomegranate juice does not impair clearance of oral or intravenous midazolam, a probe for cytochrome P450-3A activity: Comparison with grapefruit juice
Dora Farkas et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the cocktail approach
U. Fuhr et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Grapefruit-drug interactions: Can interactions with drugs be avoided?
S. U. Mertens-Talcott et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D. Demetri et al.
LANCET (2006)
The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity
Daniel Kurnik et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects
Carlo L. Bello et al.
ANTI-CANCER DRUGS (2006)
Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: Comparison with ritonavir
KE Culm-Merdek et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Variation of flavonoids and furanocoumarins in grapefruit juices: A potential source of variability in grapefruit juice-drug interaction studies
WV De Castro et al.
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY (2006)
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer
S Faivre et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B
H Satoh et al.
DRUG METABOLISM AND DISPOSITION (2005)
Undesirable effects of citrus juice on the pharmacokinetics of drugs - Focus on recent studies
M Saito et al.
DRUG SAFETY (2005)
Bergamottin contribution to the grapefruit juice-felodipine interaction and disposition in humans
TC Goosen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Two major grapefruit juice components differ in intestinal CYP3A4 inhibition kinetic and binding properties
MF Paine et al.
DRUG METABOLISM AND DISPOSITION (2004)
Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice
ML Veronese et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Time course of recovery of cytochrome P450 3A function after single doses of grapefruit juice
DJ Greenblatt et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Effect of grapefruit juice intake on etoposide bioavailability
S Reif et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine
GK Dresser et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2002)
Assessment of actual significance levels for covariate effects in NONMEM
U Wählby et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2001)
Inhibition of P-glycoprotein transport function by grapefruit juice psoralen
EJ Wang et al.
PHARMACEUTICAL RESEARCH (2001)
Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin
JJ Lilja et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2000)
分享论文
